News
CANF
3.330
-0.60%
-0.020
Can-Fite Releases Positive Data For Namodenoson In Treating Pancreatic Cancer
NASDAQ · 5d ago
Can-Fite Reports New Data Supporting Namodenoson Combo Strategy in Pancreatic Cancer
TipRanks · 5d ago
Can-Fite BioPharma Announces New Preclinical Findings Demonstrating Namodenoson Enhances Anti-Cancer Effect Of Gemcitabine Chemotherapy In Pancreatic Cancer
Benzinga · 5d ago
Weekly Report: what happened at CANF last week (0810-0814)?
Weekly Report · 5d ago
Can-Fite BioPharma Advances Phase III Drug Candidates With Strengthened FDA and EMA Pathways
TipRanks · 08/12 11:28
Weekly Report: what happened at CANF last week (0803-0807)?
Weekly Report · 08/10 09:36
Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu
TipRanks · 08/03 11:55
Can-Fite BioPharma Starts First Piclidenoson Trial in Rare Lowe Syndrome
TipRanks · 08/03 11:27
Can-Fite BioPharma Submits Phase 2 Clinical Study Protocol To Bambino Gesù Children's Hospital In Rome, Italy, For First Clinical Evaluation Of Piclidenoson In Patients With Lowe Syndrome
Benzinga · 08/03 11:03
Weekly Report: what happened at CANF last week (0727-0731)?
Weekly Report · 08/03 09:36
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
Barchart · 08/03 06:00
Weekly Report: what happened at CANF last week (0720-0724)?
Weekly Report · 07/27 09:38
Can-Fite’s Namodenoson Pancreatic Cancer Data Accepted for ESMO 2026 Presentation
TipRanks · 07/20 11:27
Can-Fite Pancreatic Cancer Data Accepted For ESMO Presentation, To Present Namodenoson Cancer Study Results At The Event
Benzinga · 07/20 11:16
Weekly Report: what happened at CANF last week (0713-0717)?
Weekly Report · 07/20 09:36
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
Barchart · 07/20 06:00
Can-Fite BioPharma Wins Australian Patent Backing Namodenoson in Liver and Pancreatic Cancer
TipRanks · 07/14 20:33
Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson
TipRanks · 07/14 11:15
Weekly Report: what happened at CANF last week (0706-0710)?
Weekly Report · 07/13 09:37
Can-Fite Completes Key Phase 3 Psoriasis Enrolment Milestone for Piclidenoson
TipRanks · 07/06 11:27
More
Webull provides a variety of real-time CANF stock news. You can receive the latest news about Can-Fite BioPharma Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About CANF
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.